Dublin, Sept. 21, 2017 -- The "World Point of Care Diagnostics Market Size and Market Share Analysis" report has been added to Research and Markets' offering.
This report estimates the point of care diagnostics testing market at $18.4 billion
World Point of Care Diagnostics Market Size and Market Share Analysis, features in-depth analysis of the market for the traditional set of point of care diagnostics tests: blood glucose testing, blood gas and electrolytes analysis, rapid coagulation testing, rapid cardiac markers diagnostics, drugs of abuse screening, urine strips testing, pregnancy testing, fecal occult blood analysis, hemoglobin diagnostics, infectious disease testing and cholesterol screening. In the past 5-10 years the following tests were added: HgA1c, B-Type Natriuretic Peptide (BNP), whole-blood lactate, D-Dimer, C-Reactive Protein (CRP).
Emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are transforming the point of care diagnostic market. The driving force behind these innovations in healthcare is to provide expedited diagnosis where the patient is seen or in the patient's home. The POC diagnostics industry will be part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine. Globally, millions of dollars are spent annually on point of care diagnostic testing, both professional testing and self-testing.
What's the size of the market opportunity in each rapid and near-patient diagnostic testing segment? Who's winning in point of care diagnostics market share? This updated superior resource, World Point of Care Diagnostics Market Size and Market Share Analysis, focuses on the global market for point of care diagnostics.
Roche, Alere, Abbott, and Siemens are among the largest companies in point of care (POC) diagnostics in terms of revenues. Together these companies make up three-fourths of the entire point of care diagnostics market. Point of care systems are designed to deliver test results in a location and timing to be useful during a patient visit. They consist of devices such as glucose meters operated by a patient or small analyzers operated in a physician office lab.
Roche dominated the point of care diagnostics market as it does in several other in IVD (in vitro diagnostics) categories. Coagulation and glucose testing are key areas. In June 2015, Roche introduced the cobas c 513 blood glucose analyzer. It is a dedicated, high-throughput HbA1c analyzer suitable for diagnosis, monitoring and risk identification of diabetes patients.
Waltham, MA-based Alere secured the second market position Alere participates in nearly all POC test segments but has a dominating position in rapid cardiac markers.
Key Topics Covered:
1: Executive Summary
2: Introduction And Overview
3: PoC Blood Glucose Tests
4: PoC Blood And Electrolytes Testing Market
5: PoC Rapid Coagulation
6: PoC Rapid Cardiac Markers
7: PoC Drug Testing
8: PoC Pregnancy And Fertility Testing
9: PoC Colon Cancer Screening/Fecal Occult Blood Testing
10: PoC Infectious Disease Testing
11: PoC Cholesterol Testing
12: PoC Cancer Tumor Marker Testing
13: PoC Urine Strip Testing
14: Miscellaneous PoC Testing
15: Issues And Trends In Point Of Care
16: Overall Global PoC Testing Market And Market Share Analysis
17: Corporate Profiles
- Abaxis
- Abbott Labs
- Abingdon Health
- Accriva
- AccuBioTech Co
- ACON
- Aerscher Diagnostics
- Alere
- Axxin
- Beckman Coulter
- Biomerica
- bioMerieux SA
- Bioptix
- biOracle Limited
- Exalenz Bioscience
- EY Laboratories
- FABPulous B.V.
- Fio Corp
- Helena Labs
- Hema Diagnostic System
- InSilixa
- Medix Biochemical
- MedMira
- Menarini Diagnostics
- Meridian BioScience
- Metaara Medical Technologies
- Nova Biomedical
- Response Biomedical
- Roche Diagnostics
- Samsung Healthcare
- Sekisui Diagnostics
- Siemens Healthcare
- Wave 80 Biosciences
- Xagenic
For more information about this report visit https://www.researchandmarkets.com/research/bh38h5/world_point_of
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Point-of-Care Diagnostics


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 



